within
typic
workflow
virtual
screen
shown
fig
compound
databas
includ
hundr
thousand
even
million
small
molecul
entri
first
screen
design
target
protein
via
method
molecular
dock
usual
molecular
dock
take
second
minut
modern
cpu
consid
flexibl
small
molecul
keep
protein
rigid
thu
virtual
screen
target
consum
great
amount
comput
resourc
supercomput
provid
next
thousand
compound
best
dock
score
kept
structur
cluster
within
cluster
compound
list
candid
compound
final
select
subsequ
valid
criteria
manual
select
druglik
properti
bind
mode
gener
molecular
dock
valid
potenc
candid
compound
variou
method
employ
includ
enzymat
activ
assay
enzymat
bind
assay
enzymat
select
assay
relationship
studi
cell
assay
recent
success
applic
virtual
screen
lab
briefli
introduc
protein
arginin
methyltransferas
prmt
import
chromatin
remodel
signal
transduct
rna
metabol
variou
diseas
cancer
cardiovascular
disord
associ
aberr
activ
prmt
combin
virtual
screen
radioact
methyl
assay
sever
hit
identifi
inhibitor
micromolar
potenc
among
hit
two
compound
show
even
higher
potenc
wellknown
prmt
inhibitor
achiev
inhibit
directli
target
substrat
rather
one
two
compound
also
significantli
inhibit
prolifer
castrateresist
prostat
cancer
cell
dna
methyltransferas
dnmt
found
mammal
attract
target
cancer
chemotherapi
first
dnmt
character
respons
maintain
dna
methyl
pattern
genom
exist
dnmt
inhibitor
nucleosid
analogu
caus
toxic
side
effect
combin
dockingbas
screen
biochem
assay
novel
nonnucleosid
inhibitor
name
identifi
inhibit
low
micromolar
concentr
remark
select
similar
methyltransferas
similaritybas
search
analogu
show
even
higher
potenc
three
compound
significantli
inhibit
prolifer
two
cancer
cell
line
polycomb
repress
complex
modul
structur
chromatin
transcript
repress
trimethyl
lysin
histon
necessari
interact
catalyt
subunit
eed
aberr
activ
broadli
implic
cancer
initi
progress
make
promis
target
cancer
therapi
combin
dockingbas
virtual
screen
biochem
assay
fdaapprov
drug
astemizol
identifi
inhibitor
interact
work
highlight
therapeut
promis
treat
human
cancer
via
target
disrupt
complex
methicillinresist
staphylococcu
aureu
mrsa
princip
caus
hospitalacquir
infect
manifest
infect
site
surgeri
bacteraemia
sepsi
frequent
prophylaxi
mrsa
infect
antibiot
fail
lead
nosocomi
diseas
clostridium
difficil
infect
due
drug
resist
sortas
transpeptidas
anchor
surfac
protein
envelop
aureu
mutant
sortas
unabl
caus
bacteraemia
sepsi
mice
virtual
screen
structur
optim
seri
inhibitor
identifi
block
activ
sortas
vitro
vivo
inhibitor
protect
mice
lethal
aureu
bacteraemia
without
affect
staphylococc
growth
vitro
thu
sortas
inhibitor
may
act
antiinfect
therapi
protect
highrisk
patient
hospitalacquir
aureu
infect
without
incur
side
effect
antibiot
rich
sourc
compound
drug
discoveri
natur
product
especi
tradit
chines
medicin
tcm
attract
attent
recent
year
variou
silico
method
appli
tcm
studi
identifi
potenti
natur
ligand
target
exampl
case
molecular
dock
discov
sieboldigenin
bind
pocket
soybean
lipoxygenas
slox
artemisia
annua
qinghao
discov
inhibitor
sarscovmpro
coronaviru
main
proteinas
combin
molecular
dock
fingerprint
studi
besid
sever
natur
product
databas
base
tcm
avail
virtualscreen
campaign
univers
natur
product
databas
chines
natur
product
databas
ismart
central
technolog
computeraid
drug
design
molecular
dock
appli
virtual
screen
drug
discoveri
also
aid
target
identif
past
year
simm
particip
research
target
identif
intern
colleagu
use
technolog
pleiotrop
lipid
mediat
act
independ
membran
receptor
intracellular
mechan
sphingosin
kinas
one
isoenzym
produc
associ
histon
regul
histon
acetyl
via
specif
bind
histon
deacetylas
inhibit
enzymat
activ
side
fingolimod
fdaapprov
drug
treatment
multipl
sclerosi
benefici
effect
central
nervou
system
independ
effect
immun
cell
traffick
although
mechan
current
well
understood
phosphoryl
nucleu
bind
inhibit
hdac
enhanc
specif
histon
acetyl
identifi
possibl
bind
mode
within
pocket
hdac
via
molecular
dock
shown
fig
conclud
may
use
adjuv
therapi
facilit
extinct
avers
memori
target
hdac
essenti
express
chemokin
recruit
mononuclear
cell
site
steril
inflamm
produc
acquir
link
polyubiquitin
mediat
inhibitor
apoptosi
enhanc
bioactiv
lipid
respons
stimul
sphingosin
kinas
respons
product
form
complex
lead
activ
confirm
directli
bind
molecular
dock
use
explor
bind
mode
tumour
necrosi
factor
tnf
receptorassoci
factor
key
compon
signal
cascad
trigger
bind
one
isoenzym
produc
prosurviv
mediat
cell
product
necessari
polyubiquitin
activ
molecular
dock
pocket
work
highlight
import
role
product
signal
canon
pathway
inflammatori
antiapoptot
immun
process
drug
target
commonli
associ
desir
therapeut
effect
unwant
advers
effect
identif
potenti
interact
help
predict
therapeut
benefit
side
effect
druglik
molecul
target
predict
identif
high
signific
drug
discoveri
research
howev
labori
timeconsum
task
undertaken
experiment
approach
alon
thu
urgent
need
develop
effici
comput
method
detect
target
chemic
compound
recent
li
et
al
develop
revers
dock
programm
tarfisdock
search
potenti
interact
screen
potenti
drug
target
databas
identif
enzym
peptid
deformylas
target
natur
product
ntranscaffeoyltyramin
helicobact
regard
success
applic
tarfisdock
liu
et
al
propos
revers
pharmacophor
map
strategi
via
web
server
call
pharmmapp
establish
predict
potenti
drug
target
exponenti
growth
bioactiv
data
becom
increasingli
difficult
handl
largescal
interact
data
small
molecul
target
via
tradit
comput
strategi
thu
target
predict
consid
big
data
problem
liu
et
al
develop
ligandbas
target
fish
method
base
fingerprint
similar
rank
data
fusion
suitabl
largescal
drug
target
predict
simpl
algorithm
fast
calcul
speed
ligandtarget
refer
librari
establish
could
updat
time
increas
avail
bioactiv
data
librari
current
contain
drug
target
activ
ligand
target
ligand
set
base
larg
refer
librari
similar
fusion
score
queri
molecul
ligand
set
calcul
correspond
target
score
molecul
use
tanimoto
coeffici
fingerprint
final
top
target
rank
fusion
score
consid
potenti
target
queri
cross
valid
adopt
evalu
perform
similar
fusion
scheme
knn
fusion
similar
ensembl
approach
sea
statisticsbas
chemoinformat
approach
also
test
parallel
fusion
scheme
comparison
demonstr
knn
fusion
perform
better
sea
refer
set
outperform
target
predict
accuraci
fusion
strategi
would
improv
increas
size
refer
set
show
strategi
could
appli
better
deal
problem
big
data
activ
ligand
two
extern
test
set
compil
drugbank
therapeut
target
databas
scheme
also
exhibit
greater
accuraci
top
predict
anoth
point
note
method
could
success
predict
new
drug
target
identifi
sea
order
verifi
effect
approach
practic
case
target
predict
made
nine
drug
withdrawn
market
herg
toxic
use
fusion
scheme
test
herg
identifi
top
target
list
drug
terfenadin
sparfloxacin
droperidol
interact
herg
rank
first
place
furthermor
therapeut
target
nine
drug
top
result
demonstr
fusion
scheme
perform
well
predict
therapeut
target
offtarget
make
method
conveni
userfriendli
web
server
develop
call
tarpr
predict
therapeut
benefit
side
effect
queri
molecul
tarpr
freeli
access
http
wwwdddcaccntarpr
chemic
queri
user
tarpr
accept
graphic
smile
format
input
calcul
take
minut
top
interact
target
rank
score
list
tarpr
also
provid
detail
inform
bindingdb
drugbank
name
gene
id
predict
diseas
diseas
inform
associ
target
extract
compar
toxicogenom
databas
integr
web
applic
inform
provid
tarpr
use
understand
function
mechan
safeti
profil
bioactiv
ligand
entecavir
salvianol
acid
b
select
case
studi
valid
effect
tarpr
result
produc
success
predict
target
quick
lowcost
method
computeraid
target
identif
play
import
role
predict
new
therapeut
target
potenti
toxic
biolog
activ
compound
drawn
increas
amount
attent
recent
year
silico
tool
tarpr
use
meaning
target
predict
sever
case
moreov
appli
prefilt
drug
develop
could
provid
crucial
guidanc
drug
repurpos
sever
onlin
web
servic
target
predict
china
summar
tabl
sever
web
servic
support
hpc
server
make
comput
time
reduc
radic
addit
platform
supercomput
simm
perform
number
calcul
regard
drug
reposit
old
drug
new
use
use
largescal
virtual
screen
earli
warn
respons
newli
emerg
infecti
diseas
becom
pandem
import
part
nation
emerg
respons
system
requir
support
hpc
period
week
month
emerg
new
infecti
diseas
critic
time
usual
absenc
effect
drug
vaccin
howev
develop
new
vaccin
take
least
month
tradit
process
develop
new
drug
requir
year
fortun
drug
discoveri
base
hpc
system
reduc
time
period
boost
social
confid
handl
epidem
situat
exampl
situat
small
molecul
flexibl
consid
alongsid
lower
calcul
precis
employ
comput
resourc
virtual
screen
almost
known
compound
world
finish
within
day
protein
flexibl
consid
higher
calcul
precis
current
comput
power
elev
one
two
order
magnitud
exascal
calcul
meet
demand
research
develop
drug
major
malign
infecti
diseas
drug
virtual
screen
becom
use
due
time
limit
fact
relat
experi
carri
directli
therefor
upon
sudden
outbreak
new
pandem
discoveri
effect
drug
new
diseas
list
current
drug
appli
highperform
comput
efficaci
way
respond
new
infecti
diseas
success
fought
sar
influenza
virus
employ
cddd
approach
hpc
discoveri
antisar
agent
silico
virtual
screen
approach
appli
small
molecul
databas
result
sever
compound
discov
potenti
drug
lead
offer
posit
measur
sar
cddd
approach
also
play
import
role
develop
famou
drug
tamiflu
use
avian
influenza
virus
design
drug
avian
influenza
virus
virtual
screen
perform
use
multipl
compound
librari
acd
cnpd
spec
compound
predict
potenti
neuraminidas
inhibitor
computeraid
structur
modif
drug
synthesi
perform
nearli
analogu
oseltamivir
zanamivir
design
synthesis
total
neuraminidas
inhibitor
avian
influenza
discov
enzym
activ
similar
zanamivir
effect
vivo
inhibitor
possess
independ
intellectu
properti
right
satisfactori
activ
sever
lead
compound
innov
structur
independ
intellectu
properti
right
activ
similar
zanamivir
act
viru
viral
level
acquir
furthermor
drug
candid
preclin
studi
determin
therefor
evid
virtual
screen
base
hpc
system
remark
improv
effici
drug
discoveri
drug
compound
optimis
recent
virtual
screen
platform
develop
combin
nudt
simm
nation
supercomput
center
guangzhou
mani
integr
core
enabl
version
author
acceler
lamarckian
genet
algorithm
deepli
achiev
sppdup
base
platform
simm
carri
virtual
screen
project
ebola
viru
use
resourc
virtual
screen
task
small
chemic
complet
within
day
combin
hpc
higheffici
platform
enabl
countri
abil
deal
superhighthroughput
screen
task
handl
acut
infecti
diseas
singl
photograph
runner
tell
littl
stride
static
model
produc
nmr
xray
crystallographi
provid
limit
inform
meanwhil
md
simul
deliv
ensembl
conform
promot
understand
dynam
process
underli
receptor
activ
md
simul
apo
glucagon
receptor
gcgr
glucagonbound
gcgr
perform
use
packag
recent
discov
fulllength
gcgr
potenti
drug
target
type
diabet
two
conform
open
conform
stabil
peptid
glucagon
close
conform
apogcgr
extracellular
domain
ecd
form
extens
contact
seven
transmembran
domain
fig
two
conform
differ
fulllength
gcgrglucagon
model
construct
use
crystal
structur
fig
first
report
put
close
state
gcgr
atom
level
consist
hydrogendeuterium
exchang
hdx
result
valid
disulphid
crosslink
studi
gcgr
belong
secretinlik
class
famili
gproteincoupl
receptor
gpcr
human
activ
endogen
hormon
peptid
play
causal
role
mani
diseas
rang
diabet
osteoporosi
anxieti
sever
conserv
structur
featur
ligand
interact
hotspot
secretinlik
class
b
gpcr
rel
movement
interact
dynam
ecd
domain
fulllength
gcgr
provid
use
inform
guid
design
new
experi
investig
class
b
gpcr
relationship
addit
protein
motion
offer
md
simul
provid
essenti
inform
identif
druggabl
alloster
site
visibl
static
structur
previou
studi
shown
voltagesensor
domain
vsd
shaker
chimaer
channel
member
voltageg
potassium
kv
channel
occlud
shown
simul
intern
extern
water
crevic
fig
howev
simul
channel
anoth
member
kv
channel
antiepilepsi
target
caviti
fill
water
molecul
appear
vsd
fig
volum
space
guess
potentialbind
pocket
locat
vsd
base
dock
model
activ
report
previous
homolog
model
one
md
simul
complex
conduct
use
gromac
packag
provid
structur
bind
model
mutagenesi
electrophysiolog
studi
valid
activatorbind
pocket
vsd
fig
subsequ
structurebas
virtual
screen
target
identifi
pocket
discov
nine
activ
five
new
chemotyp
two
exhibit
signific
antiepilepsi
activ
fig
result
demonstr
capabl
vsd
accommod
small
chemic
ligand
new
function
gate
charg
pathway
offer
new
insight
therapeut
relev
channel
biomacromolecul
share
highsequ
ident
well
similar
structur
play
distinct
role
patholog
besid
subtl
differ
environ
belong
interact
surround
small
molecul
contribut
differ
function
md
simul
enabl
us
investig
atom
interact
detail
level
success
appli
identifi
predict
differenti
regul
highli
homolog
receptor
exampl
first
show
success
applic
predict
interact
channel
phospholipid
compon
enrich
plasma
membran
substrat
number
import
signal
protein
includ
kv
channel
though
alter
physiolog
function
pharmacolog
select
kcnq
channel
effect
interact
kcnq
channel
well
understood
predict
interact
channel
ns
allatom
md
simul
open
close
conform
channel
perform
use
gromac
packag
simul
two
differ
forc
field
yield
similar
interact
preferenti
interact
linker
openst
channel
wherea
contact
posit
residu
loop
close
state
fig
interact
differ
interact
consist
effect
also
differ
rel
shaker
channel
result
indic
divers
effect
kv
channel
mechan
propos
action
channel
consist
report
subtyp
sensit
kv
channel
indic
may
exert
specif
effect
channel
thu
md
simul
effect
method
analys
interact
md
simul
also
success
appli
identifi
cholesterol
bind
varieti
gpcr
interest
two
major
receptor
subtyp
share
sequenc
ident
highli
similar
structur
distinct
sometim
oppos
effect
cardiovascular
physiolog
pathogenesi
heart
failur
subtyp
specif
compartment
cholesterolenrich
caveola
lipid
raft
two
md
simul
embed
phosphatidylcholinecholesterol
mixtur
membran
perform
use
gromac
packag
compar
potenti
cholesterolbind
site
big
differ
observ
cholesterol
interact
site
relev
cholesterolmedi
dimeris
alloster
regul
receptor
activ
md
simul
provid
valuabl
clue
regard
cholesterol
bind
shed
light
gener
determin
cholesterol
bind
gpcr
thank
effici
comput
resourc
nation
supercomput
center
jinan
nation
supercomput
center
tianjin
tianh
research
develop
team
nudt
abovement
studi
accomplish
biolog
system
studi
use
allatom
md
simul
larg
compris
million
atom
calcul
requir
often
complex
comput
intens
even
best
supercomput
clear
room
improv
steadi
growth
hpc
made
md
simul
span
wider
spatial
tempor
rang
resolut
like
play
increasingli
import
role
develop
novel
pharmacolog
therapeut
largescal
conform
chang
protein
relat
biolog
function
protein
also
associ
bind
ligand
drug
md
simul
emerg
practic
approach
explor
protein
dynam
still
unequ
gener
applic
strategi
explor
largescal
protein
conform
transit
consid
structur
new
gener
supercomput
develop
new
approach
call
numd
deal
largescal
protein
conform
movement
combin
normal
mode
analysi
umbrella
sampl
md
simul
new
approach
produc
thousand
protein
conform
along
conform
transit
pathway
conform
simul
simultan
thousand
cpu
therefor
compar
wide
use
md
approach
includ
namd
gromac
amber
new
code
specif
suitabl
hpc
delin
atom
detail
conform
transit
pathway
associ
free
energi
landscap
applic
three
wellknown
protein
system
adenyl
kinas
adk
calmodulin
cam
kinas
absenc
presenc
respect
ligand
reveal
predict
conform
transit
pathway
thermodynam
observ
good
agreement
experiment
comput
determin
one
fig
thu
simpl
approach
offer
gener
applic
strategi
use
hpc
probe
intrins
ligandinduc
largescal
protein
conform
transit
associ
free
energi
landscap
protein
fold
physic
process
polypeptid
fold
structur
random
coil
characterist
protein
function
shape
conform
correctli
fold
protein
structur
conform
essenti
protein
biolog
function
failur
fold
nativ
structur
may
produc
inact
protein
misfold
protein
may
also
modifi
toxic
function
exampl
aggreg
protein
associ
ill
alzheim
diseas
ad
parkinson
diseas
md
simul
good
tool
studi
protein
fold
dynam
silico
ad
progress
irrevers
neurolog
disord
frequent
caus
senil
dementia
two
patholog
character
hallmark
ad
appear
extracellular
senil
plaqu
intracellular
neurofibrillari
tangl
major
constitu
plaqu
amyloid
amino
acid
produc
sequenti
action
amyloid
precursor
protein
two
abund
isoform
differ
found
ctermini
latter
two
hydrophob
residu
demonstr
neurotox
increas
concentr
ratio
correl
onset
ad
extens
experiment
theoret
studi
explor
structur
monomer
well
aggreg
reveal
remark
molecularlevel
insight
includ
key
point
structur
featur
associ
differ
morpholog
distinct
impli
peptid
abl
adopt
divers
set
conform
antiparallel
parallel
often
key
structur
element
dire
need
structur
studi
monom
aggreg
atom
level
answer
crucial
question
structur
form
aggreg
rapidli
sever
view
high
propens
selfassembl
md
simul
complementari
standard
tool
structur
biolog
nmr
xray
diffract
appear
use
tool
obtain
atom
level
insight
structur
well
conform
chang
prerequisit
develop
specif
drug
optim
affin
monom
toxic
oligom
perform
multipl
parallel
md
simul
total
ns
wildtyp
peptid
mutant
aqueou
solut
conform
transit
observ
complet
unfold
process
peptid
helix
coil
trace
md
simul
structur
short
helic
identifi
intermedi
state
unfold
pathway
fig
four
tandem
glycin
ctermin
found
account
short
format
mutat
glycin
alanin
almost
abolish
format
increas
content
helix
compon
instead
fig
lipid
bilay
dipalmitoyl
phosphatidylcholin
major
secondari
structur
helic
howev
peptid
tend
exit
hydrophob
region
lie
surfac
bilay
overal
result
provid
annot
conform
transit
relat
dynam
process
exit
membran
enter
aqueou
solut
benefici
understand
underli
molecular
mechan
aggreg
design
compound
inhibit
format
oligom
well
amyloid
fibril
fig
intermedi
structur
reveal
simul
core
domain
constitut
segment
residu
four
residu
essenti
format
chemic
compound
lock
structur
intermedi
state
could
possibl
inhibit
fibril
target
intermedi
structur
virtual
screen
base
molecular
dock
perform
goal
discov
small
molecul
inhibitor
interrupt
format
pleat
structur
involv
amyloid
fibril
via
bind
intermedi
structur
one
dock
compound
shown
effect
inhibit
aggreg
fibril
thioflavin
fluoresc
assay
atom
forc
microscopi
polyacrylamid
gel
electrophoresi
analysi
meanwhil
cd
spectroscopi
measur
reveal
compon
increas
presenc
suggest
bind
stabil
structur
peptid
taken
togeth
studi
demonstr
intermedi
structur
reveal
aforement
simul
could
use
bind
target
inhibitor
design
also
provid
new
insight
molecular
event
involv
conform
transit
peptid
fibrillogenesi
subsequ
structur
optim
perform
nine
compound
higher
potenc
obtain
particular
one
nine
new
compound
suppress
aggreg
also
dissolv
preform
fibril
vitro
cellular
assay
reveal
toxic
neuron
cell
moreov
effect
inhibit
neurotox
increas
cell
viabil
therefor
base
upon
intermedi
structur
reveal
md
simul
virtual
screen
togeth
structur
optim
result
lead
compound
develop
drug
ad
character
conform
dynam
monomer
prerequisit
comprehend
selfassembl
pathway
differ
two
peptid
recent
studi
set
investig
conform
dynam
explor
impact
intramolecular
interact
conform
dynam
use
equilibrium
md
simul
simul
reveal
heterogen
conform
ensembl
encompass
unstructur
coil
two
conform
state
identifi
isoform
collaps
state
cs
resembl
structur
motif
facetofac
hydrophob
cluster
amyloid
fibril
extend
state
es
carri
structur
featur
antiparallel
observ
amyloid
oligom
observ
line
previou
nmr
studi
cterminu
remain
unstructur
rare
interact
part
therefor
hydrophob
cluster
loos
structur
peptid
assum
es
high
probabl
contrast
cterminu
adopt
structur
strongli
interact
segment
activ
associ
extra
lead
compact
hydrophob
collaps
prevent
isoform
form
es
base
structur
character
propos
aggreg
begin
cs
propens
variou
isoform
selfassoci
particular
form
encod
equilibrium
conform
state
simul
result
demonstr
probabl
stay
cs
significantli
higher
enhanc
aggreg
propens
former
could
result
consequ
lower
energi
barrier
nucleat
format
besid
greater
resembl
fibril
structur
observ
cs
includ
increas
occup
compact
hydrophob
collaps
structur
advantag
could
also
contribut
effect
nucleat
precis
medicin
also
known
medicin
refer
predict
person
prevent
participatori
medicin
owe
rapid
pace
human
genom
research
highthroughput
technolog
person
medicin
expect
becom
new
paradigm
futur
healthcar
person
medicin
like
affect
societi
mani
aspect
radic
chang
medic
practic
pharmaceut
industri
involv
current
person
medicin
lead
third
wave
drug
discoveri
unit
state
introduc
precis
medicin
initi
earli
order
promot
develop
person
medicin
hope
lead
new
era
medic
healthcar
rapid
develop
supercomput
play
signific
role
develop
precis
medicin
greatli
strengthen
comput
data
analysi
abil
genom
vigor
promot
highperform
comput
precis
medicin
base
genom
person
drug
research
discoveri
greatli
improv
therapeut
effect
employ
person
accur
treatment
remedi
case
discoveri
valid
function
gene
target
earli
stage
drug
research
develop
lead
discoveri
optim
platform
drug
virtual
screen
design
must
base
hpc
infrastructur
rapid
improv
comput
technolog
expens
genom
sequenc
drop
besid
inform
technolog
appli
biomedicin
make
patient
achiev
health
inform
process
person
drug
develop
requir
integr
medic
data
well
biolog
inform
divers
omic
level
includ
dna
rna
protein
network
cell
metabolit
tissu
integr
biomed
inform
also
involv
regul
network
multipl
gene
target
word
comput
genom
comput
proteom
comput
regul
network
comput
drug
design
play
crucial
indispens
role
process
person
medicin
discoveri
howev
signific
comput
resourc
requir
process
hpc
infrastructur
play
increasingli
import
role
deal
task
big
data
biomedicin
refer
increas
avail
explos
growth
medic
data
biolog
inform
provid
opportun
futur
biomed
research
person
medicin
studi
also
requir
new
gener
hpc
architectur
divers
technolog
data
mine
system
includ
omic
inform
inscript
data
clinic
data
even
financi
data
conclus
age
precis
medicin
big
data
opportun
challeng
exist
togeth
hpc
system
increasingli
essenti
compon
comput
analys
integr
raw
data
effici
larg
size
biomed
data
order
make
person
medicin
effici
accur
tool
algorithm
integr
analys
biomed
data
need
develop
improv
